MLICM
NAGE

Metropolitan Life Insurance Company (MetLife)’s Niagen Bioscience NAGE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,355
Closed -$33.6K – 2839
2021
Q3 		$33.6K Sell
5,355
-7,415
-58% -$61.1K ﹤0.01% 2797
2021
Q2 		$126K Buy
12,770
+1,604
+14% +$14K ﹤0.01% 2470
2021
Q1 		$104K Buy
+11,166
New +$88.5K ﹤0.01% 2411

Other funds holding NAGE

YRHAM
Yong Rong (HK) Asset Management Sheung Wan, Hong Kong $119M AUM 233.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NAGE Position: Q4 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Niagen Bioscience (NAGE) in Q4 2021, closing a stake of 5,355 shares — an estimated $33.6K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NAGE in Q1 2021 and held it in 3 quarters. The position peaked at $126K in Q2 2021. 83 funds tracked by Wall St. Rank hold NAGE as of Q4 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Niagen Bioscience position as of Q4 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,355 Niagen Bioscience shares in Q4 2021, an estimated $33.6K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Niagen Bioscience in Q1 2021 and held it in 3 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Niagen Bioscience position peaked at $126K in Q2 2021.
  • 83 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2021, filed 15 Feb 2022.